Azitra Inc (AZTR)
XASE:AZTR
Want to see AZTR full AI Analyst Report?
AZTR Stock Chart & Stats
$0.30
-$0.02(-5.17%)
At close: 4:00 PM EST
$0.30
-$0.02(-5.17%)
Day’s Range― - ―
52-Week Range$0.10 - $2.40
Previous CloseN/A
Volume201.32K
Average Volume (3M)169.78K
Market Cap
$3.62M
Enterprise Value-$9.71B
Total Cash (Recent Filing)$10.05M
Total Debt (Recent Filing)$443.79K
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 17, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding16,192,438
10 Day Avg. Volume152,326
30 Day Avg. Volume169,784
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap-2.68K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.51K
Enterprise Value/Ebitda882.83
Forecast
1Y Price Target
$1.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Strain Library & AIAzitra's large, curated microbial library plus AI/ML discovery tools is a durable platform advantage. It enables repeated R&D campaigns, faster lead identification, and proprietary IP across multiple indications and ingredients, supporting long-term pipeline depth and optionality.
Niche Rare Dermatology FocusTargeting rare, high-unmet-need dermatologic conditions creates structural upside: clearer regulatory pathways, limited competition, and higher clinical value per approved product. This niche positioning supports sustainable commercial potential if development milestones are met.
PIPE Financing Extends RunwayThe completed PIPE provides near-term capital to fund R&D and cosmeceutical program launches, reducing immediate financing pressure. That funding materially improves the company's ability to advance programs and pursue commercialization steps over the next several quarters.
Bears Say
Revenue Collapsed To $0A drop to zero reported revenue in 2025/TTM signals absence of recurring commercial sales and weak monetization of assets. This undermines self-funding prospects, raises financing reliance, and suggests commercial execution or product-readiness shortfalls that impair long-term sustainability.
Persistent Negative Cash FlowConsistent and worsening negative operating and free cash flow indicates ongoing cash burn translating from losses into real outflows. This forces repeated financing, increases dilution risk, limits strategic flexibility, and can slow or halt program progression absent durable capital sources.
Listing & Governance RiskNYSE noncompliance, delisting risk, adjourned and canceled shareholder meetings signal governance and listing fragility. These structural issues can deter institutional investors, complicate future financings, distract management with remediation, and threaten market access if unresolved.
Azitra Inc News
AZTR FAQ
What was Azitra Inc’s price range in the past 12 months?
Azitra Inc lowest stock price was $0.10 and its highest was $2.40 in the past 12 months.
What is Azitra Inc’s market cap?
Azitra Inc’s market cap is $3.62M.
When is Azitra Inc’s upcoming earnings report date?
Azitra Inc’s upcoming earnings report date is Aug 17, 2026 which is in 73 days.
How were Azitra Inc’s earnings last quarter?
Azitra Inc released its earnings results on May 13, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.24.
Is Azitra Inc overvalued?
According to Wall Street analysts Azitra Inc’s price is currently Undervalued.
Does Azitra Inc pay dividends?
Azitra Inc does not currently pay dividends.
What is Azitra Inc’s EPS estimate?
Azitra Inc’s EPS estimate is -0.12.
How many shares outstanding does Azitra Inc have?
Azitra Inc has 16,192,438 shares outstanding.
What happened to Azitra Inc’s price movement after its last earnings report?
Azitra Inc reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -1.818%.
Which hedge fund is a major shareholder of Azitra Inc?
Currently, no hedge funds are holding shares in AZTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Azitra Inc
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
AZTR Stock 12 Month Forecast
Average Price Target
$1.00
▲(233.33% Upside)
Technical Analysis
Ownership Overview
4.47%
Insiders
0.47% Mutual Funds
0.14% Other Institutional Investors
94.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---